Use of renin-angiotensin system blockade in patients with renal artery stenosis. 2014

Jordana B Cohen, and Raymond R Townsend
Renal, Electrolyte, and Hypertension Division, University of Pennsylvania, Philadelphia, Pennsylvania.

UI MeSH Term Description Entries
D008297 Male Males
D012078 Renal Artery Obstruction Narrowing or occlusion of the RENAL ARTERY or arteries. It is due usually to ATHEROSCLEROSIS; FIBROMUSCULAR DYSPLASIA; THROMBOSIS; EMBOLISM, or external pressure. The reduced renal perfusion can lead to renovascular hypertension (HYPERTENSION, RENOVASCULAR). Renal Artery Stenosis,Obstruction, Renal Artery,Obstructions, Renal Artery,Renal Artery Obstructions,Renal Artery Stenoses,Stenoses, Renal Artery,Stenosis, Renal Artery
D012084 Renin-Angiotensin System A BLOOD PRESSURE regulating system of interacting components that include RENIN; ANGIOTENSINOGEN; ANGIOTENSIN CONVERTING ENZYME; ANGIOTENSIN I; ANGIOTENSIN II; and angiotensinase. Renin, an enzyme produced in the kidney, acts on angiotensinogen, an alpha-2 globulin produced by the liver, forming ANGIOTENSIN I. Angiotensin-converting enzyme, contained in the lung, acts on angiotensin I in the plasma converting it to ANGIOTENSIN II, an extremely powerful vasoconstrictor. Angiotensin II causes contraction of the arteriolar and renal VASCULAR SMOOTH MUSCLE, leading to retention of salt and water in the KIDNEY and increased arterial blood pressure. In addition, angiotensin II stimulates the release of ALDOSTERONE from the ADRENAL CORTEX, which in turn also increases salt and water retention in the kidney. Angiotensin-converting enzyme also breaks down BRADYKININ, a powerful vasodilator and component of the KALLIKREIN-KININ SYSTEM. Renin-Angiotensin-Aldosterone System,Renin Angiotensin Aldosterone System,Renin Angiotensin System,System, Renin-Angiotensin,System, Renin-Angiotensin-Aldosterone
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000806 Angiotensin-Converting Enzyme Inhibitors A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. ACE Inhibitor,ACE Inhibitors,Angiotensin Converting Enzyme Inhibitor,Angiotensin I-Converting Enzyme Inhibitor,Angiotensin-Converting Enzyme Inhibitor,Kininase II Inhibitor,Kininase II Inhibitors,Angiotensin I-Converting Enzyme Inhibitors,Angiotensin-Converting Enzyme Antagonists,Antagonists, Angiotensin-Converting Enzyme,Antagonists, Kininase II,Inhibitors, ACE,Inhibitors, Angiotensin-Converting Enzyme,Inhibitors, Kininase II,Kininase II Antagonists,Angiotensin Converting Enzyme Antagonists,Angiotensin Converting Enzyme Inhibitors,Angiotensin I Converting Enzyme Inhibitor,Angiotensin I Converting Enzyme Inhibitors,Antagonists, Angiotensin Converting Enzyme,Enzyme Antagonists, Angiotensin-Converting,Enzyme Inhibitor, Angiotensin-Converting,Enzyme Inhibitors, Angiotensin-Converting,II Inhibitor, Kininase,Inhibitor, ACE,Inhibitor, Angiotensin-Converting Enzyme,Inhibitor, Kininase II,Inhibitors, Angiotensin Converting Enzyme
D047228 Angiotensin II Type 1 Receptor Blockers Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. Angiotensin II Type 1 Receptor Antagonist,Angiotensin II Type 1 Receptor Blocker,Sartan,Angiotensin 2 Type 1 Receptor Antagonists,Angiotensin II Type 1 Receptor Antagonists,Sartans,Selective Angiotensin II Receptor Antagonists,Type 1 Angiotensin Receptor Antagonists,Type 1 Angiotensin Receptor Blockers
D050197 Atherosclerosis A thickening and loss of elasticity of the walls of ARTERIES that occurs with formation of ATHEROSCLEROTIC PLAQUES within the ARTERIAL INTIMA. Atherogenesis,Atherogeneses,Atheroscleroses

Related Publications

Jordana B Cohen, and Raymond R Townsend
October 2013, Current hypertension reports,
Jordana B Cohen, and Raymond R Townsend
December 2007, Hypertension (Dallas, Tex. : 1979),
Jordana B Cohen, and Raymond R Townsend
July 2014, Clinical journal of the American Society of Nephrology : CJASN,
Jordana B Cohen, and Raymond R Townsend
March 1998, Current opinion in nephrology and hypertension,
Jordana B Cohen, and Raymond R Townsend
October 2012, International urology and nephrology,
Jordana B Cohen, and Raymond R Townsend
June 2017, Critical care medicine,
Jordana B Cohen, and Raymond R Townsend
January 2002, Current opinion in nephrology and hypertension,
Jordana B Cohen, and Raymond R Townsend
November 1999, Hypertension (Dallas, Tex. : 1979),
Jordana B Cohen, and Raymond R Townsend
July 2014, Pediatric nephrology (Berlin, Germany),
Jordana B Cohen, and Raymond R Townsend
January 2009, International urology and nephrology,
Copied contents to your clipboard!